Synapse - Works

Results (116149)

Redefining the IGCCCG classification in advanced non-seminoma

Meeting Abstract

Gillessen, S.; Collette, L.; Daugaard, G.; de Wit, R.; Tryakin, A.; Albany, C.; Stahl, O.; Fizazi, K.; Gietema, J. A.; De Giorgi, U. F. F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

Meeting Abstract

Choueiri, T. K.; Larkin, J. M. G.; Pal, S. K.; Motzer, R. J.; Venugopal, B.; Alekseev, B. Y.; Miyake, H.; Gravis, G.; Bilen, M. A.; Chudnovsky, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Meeting Abstract

Van Cutsem, E.; Golan, T.; Hammel, P.; Reni, M.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients

Meeting Abstract

Awada, A. H.; Harding, J. J.; Kotecki, N.; Aftimos, P. G.; Decaens, T.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Serdjebi, C.; Halfon, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study

Meeting Abstract

Freemantle, N.; Abou-Alfa, G. K.; Cheng, A. L.; Kelley, R. K.; Valcheva, V.; Benzaghou, F.; Mollon, P.
Annals of Oncology (2019)

Fulltext@MSK | Save

GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2(+)/HER2(-) locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Meeting Abstract

Shah, M.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shitara, K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Meeting Abstract

Abida, W.; Campbell, D.; Patnaik, A.; Sautois, B.; Shapiro, J.; Vogelzang, N. J.; Bryce, A. H.; McDermott, R.; Ricci, F.; Rowe, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients

Meeting Abstract

Italiano, A.; Nanda, S.; Keating, K.; Childs, B. H.; Fellous, M.; Drilon, A.; Hyman, D. M.
Annals of Oncology (2019)

Fulltext@MSK | Save

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Meeting Abstract

Drilon, A.; Rogers, E.; Zhai, D.; Deng, W.; Zhang, X.; Lee, D.; Ung, J.; Whitten, J.; Zhang, H.; Liu, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Meeting Abstract

Hammel, P.; Kindler, H. L.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save